OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone305-575-4100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.07 billion
Profitability
Miscellaneous
Employees6,030
OptionableOptionable
Opko Health (NASDAQ:OPK) Frequently Asked Questions
What is Opko Health's stock symbol?
Opko Health trades on the NASDAQ under the ticker symbol "OPK."
How were Opko Health's earnings last quarter?
Opko Health Inc. (NASDAQ:OPK) released its quarterly earnings data on Friday, November, 9th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. The biotechnology company earned $250 million during the quarter, compared to analysts' expectations of $264.04 million. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The firm's quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.08) EPS. View Opko Health's Earnings History.
When is Opko Health's next earnings date?
What price target have analysts set for OPK?
3 equities research analysts have issued 1-year price targets for Opko Health's shares. Their forecasts range from $7.00 to $20.00. On average, they expect Opko Health's share price to reach $11.3333 in the next twelve months. This suggests a possible upside of 208.0% from the stock's current price. View Analyst Price Targets for Opko Health.
What is the consensus analysts' recommendation for Opko Health?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Opko Health.
What are Wall Street analysts saying about Opko Health stock?
Here are some recent quotes from research analysts about Opko Health stock:
- 1. According to Zacks Investment Research, "OPKO Health exited the third quarter on a mixed note. While loss per share was narrower-than-expected, revenues topped the Zacks Consensus Estimate. Contribution from RAYALDEE was significant. Furthermore, OPKO Health’s utilization of the 4Kscore remains strong, with 8,700 tests registered in the third quarter. OPKO has also completed a Premarket Approval (PMA) submission for Claros point-of-care PSA test to the FDA. Additionally, tests like testosterone and Vitamin D utilizing the Claros platform are advancing toward a 510(k) submission to the FDA. Several metabolic and endocrinology programs that are underway, are likely to provide OPKO Health a competitive advantage. Meanwhile, the margins look pressed at the moment. Also, the company’s core segmental revenues remain weak in the quarter. Moreover, the decline in R&D expenses indicates reduced focus on innovation. OPKO Health underperformed its industry in a year's time. " (11/30/2018)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline." (11/12/2018)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month price target of $20 for OPK shares post a 2Q18 EPS beat. We continue to think that the long-term sales and earnings potential of OPK’s business is underappreciated and that upward earnings revisions in 2019+ to levels not reflected in consensus expectations should drive the stock higher. We expect upward earnings revisions to come from the uptake of Rayaldee, commercialization of OPK’s branded drug pipeline, and BioReference sales growth and margin expansion." (8/7/2018)
Has Opko Health been receiving favorable news coverage?
News articles about OPK stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opko Health earned a news impact score of 1.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Are investors shorting Opko Health?
Opko Health saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 56,212,686 shares, a decline of 9.8% from the December 14th total of 62,293,145 shares. Based on an average trading volume of 8,289,847 shares, the short-interest ratio is presently 6.8 days. Approximately 18.5% of the company's shares are short sold. View Opko Health's Current Options Chain.
Who are some of Opko Health's key competitors?
Some companies that are related to Opko Health include Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Catalent (CTLT) and United Therapeutics (UTHR).
Who are Opko Health's key executives?
Opko Health's management team includes the folowing people:
- Dr. Phillip Frost, Chairman & CEO (Age 82)
- Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 71)
- Mr. Adam E. Logal, Sr. VP & CFO (Age 40)
- Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 58)
- Ms. Kate Inman, Gen. Counsel & Sec. (Age 45)
Who are Opko Health's major shareholders?
Opko Health's stock is owned by a number of of retail and institutional investors. Top institutional investors include RK Asset Management LLC (0.18%), Cumberland Advisors Inc. (0.00%), Douglas Lane & Associates LLC (0.00%) and Diversified Trust Co (0.00%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health.
Which major investors are selling Opko Health stock?
Which major investors are buying Opko Health stock?
OPK stock was purchased by a variety of institutional investors in the last quarter, including Cumberland Advisors Inc., Douglas Lane & Associates LLC and Diversified Trust Co. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Opko Health, Inc, Phillip Md Et Al Frost, Richard A Lerner, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health.
How do I buy shares of Opko Health?
Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opko Health's stock price today?
One share of OPK stock can currently be purchased for approximately $3.68.
How big of a company is Opko Health?
Opko Health has a market capitalization of $2.06 billion and generates $1.07 billion in revenue each year. The biotechnology company earns $-308,870,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Opko Health employs 6,030 workers across the globe.
What is Opko Health's official website?
How can I contact Opko Health?
Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]
MarketBeat Community Rating for Opko Health (NASDAQ OPK)
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
